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http://dx.doi.org/10.10physiological and psychological factors. Nutritional compounds are postulated to play a role in the
pathophysiological processes that are affected in AD. We here provide the first systematic review
and meta-analysis that compares plasma levels of micronutrients and fatty acids in AD patients to
those in cognitively intact elderly controls. A secondary objective was to explore the presence of dif-
ferent plasma nutrient levels between AD and control populations that did not differ in measures of
protein/energy nourishment.
Methods: We screened literature published after 1990 in the Cochrane Central Register of Con-
trolled Trials, Medline, and Embase electronic databases using Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses (PRISMA) guidelines for AD patients, controls, micronutrient,
vitamins, and fatty acids, resulting in 3397 publications, of which 80 met all inclusion criteria. Sta-
tus of protein/energy malnutrition was assessed by body mass index, mini nutritional assessment
score, or plasma albumin. Meta-analysis, with correction for differences in mean age between
AD patients and controls, was performed when more than five publications were retrieved for a spe-
cific nutrient.
Results: We identified five or more studies for folate, vitamin A, vitamin B12, vitamin C, vitamin
D, vitamin E, copper, iron, and zinc but fewer than five studies for vitamins B1 and B6, long-chain
omega-3 fatty acids, calcium, magnesium, manganese, and selenium (the results of the individual
publications are discussed). Meta-analysis showed significantly lower plasma levels of folate and
vitamin A, vitamin B12, vitamin C, and vitamin E (P , .001), whereas nonsignificantly lower
levels of zinc (P 5 .050) and vitamin D (P 5 .075) were found in AD patients. No significant dif-
ferences were observed for plasma levels of copper and iron. A meta-analysis that was limited to
studies reporting no differences in protein/energy malnourishment between AD and control popu-
lations yielded similar significantly lower plasma levels of folate and vitamin B12, vitamin C, and
vitamin E in AD.
Conclusions: The lower plasma nutrient levels indicate that patients with AD have impaired sys-
temic availability of several nutrients. This difference appears to be unrelated to the classic malnour-
ishment that is well known to be common in AD, suggesting that compromised micronutrient status
may precede protein and energymalnutrition. Contributing factors might be AD-related alterations in
feeding behavior and intake, nutrient absorption, alterations in metabolism, and increased
utilization of nutrients for AD pathology-related processes. Given the potential role of nutrients inuthor. Tel.: 131-30-209-5000 (direct line - 5545);
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and offer potential in AD management.
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Alzheimer’s disease (AD) is a neurodegenerative disorder
of unknown origin and the leading cause of dementia. Age is
the primary risk factor for AD [1,2], whereas a family history
of AD (in familial AD) and the presence of the ApoE4
genotype (in sporadic AD) are the most important
inherited determinants known for this disease [3,4]. Other
risk factors for AD include gender, education, and
potentially modifiable lifestyle factors including diet and
physical activity [5,6]. Diet-related disorders such as obe-
sity, hypertension, hypercholesterolemia, and diabetes
have consistently been shown to be associated with AD
[7–9]. Risk factors of nutritional origin are extensively
analyzed for their possible role in AD onset and
progression [3,10–13]. Epidemiological studies have
suggested a positive correlation between AD and the
consumption of a diet rich in saturated fatty acids and
alcohol and low in antioxidants and vitamins. However,
adherence to a diet rich in fruits, vegetables, and
unsaturated fatty acids and low in saturated fat and refined
sugar seems to reduce the risk of dementia and cognitive
decline [10,14–17].
The first nutrients identified to be of pivotal importance
for neuronal functioning and cognition were the B vitamins
[18]. They were discovered at the beginning of the 20th cen-
tury as being essential nutrients able to relieve beriberi and
pellagra, deficiency diseases affecting the nervous system
[19]. In 1929, Frederick Gowland Hopkins [20] and Chris-
tiaan Eijkman were awarded the Nobel Prize in Physiology
for this discovery. Since then, several nutrients, including
antioxidants, choline, and omega-3 fatty acids, have been
suggested to influence cerebral functioning (reviewed in
Bourre [21] and in Smith and Blumenthal [22]).
Therefore, it is no surprise that these nutrients have been
postulated to play roles in the pathophysiological processes
in AD. For example, antioxidants reduce reactive-oxygen-
species-induced damage and stabilize membranes; the fatty
acid docosahexaenoic acid (DHA) affects abnormal protein
processing (amyloid-b, tau); and DHA, choline, and uridine
modulate neuronal membrane formation [23]. Recent evi-
dence suggests that a multinutrient intervention comprising
DHA, eicosapentaenoic acid (EPA), uridine monophosphate
(UMP), choline, folate, vitamin B6, vitamin B12, vitamin C,
vitamin E, selenium, and phospholipids (PLs) modulated
functional connectivity measures (assessed by electroen-
cephalography) in AD, indicative of preserved synaptic
function [24]. Therefore, increasing specific nutrient levelsmay modulate synaptic function and prevent neurodegener-
ation and eventually neuronal loss. Despite the potential im-
portance of nutrient availability for brain function in AD,
evidence on its systemic availability in AD is not conclusive.
The results of the many studies that examined plasma nutri-
ent levels in AD are not fully consistent, and systematic re-
views are lacking.
The primary objective of the current systematic review is
to evaluate the presence of differences in the systemic avail-
ability of nutrients between AD patients and cognitively in-
tact elderly controls. Because protein/energy malnutrition
may be present more among patients with AD than among
control subjects and can potentially be associated with dif-
ferential micronutrient and fatty acid status, the secondary
objective was to compare plasma nutrient levels of AD pa-
tients and controls that were reported not to differ in mea-
sures of protein/energy malnourishment. All relevant
literature published after 1990 in Medline, Embase, and
the Cochrane Central Register of Controlled Trials was re-
viewed using the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) guidelines recently
published by Moher and colleagues [25].2. Methods
2.1. Search strategy and selection criteria
The literature published from 1990 to March 26, 2012
was systematically screened in the Cochrane Central Reg-
ister of Controlled Trials, Medline, and Embase electronic
databases according to PRISMA guidelines [25] using the
following search terms in the title, abstract, or descrip-
tors:
(Alzheimer* and [humans or patients or inpatients or
outpatients or persons or volunteers or participants or sub-
jects] and [nutrition or nutritional or nutrient or nutrients or
micronutrient or micronutrients or diet or diets or dietary or
vitamin or vitamins or mineral or minerals or trace-element
or trace-elements or fatty-acid or fatty-acids or pufa or pu-
fas])
The search in the Cochrane Central Register of Con-
trolled Trials, Embase, and Medline resulted in 4768 pub-
lished studies that were imported into Endnote. Duplicate
references (684) were automatically removed, followed by
manual examination, which retrieved another 687 duplicate
references. The title and abstract of the remaining 3397 pub-
lications were evaluated according to predefined exclusion
and inclusion criteria.
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trient levels of AD patients, even if not explicitly mentioned
in the abstract. One fifth (724) of the retrieved publications
was identified to be of potential relevance. The full-text ar-
ticles of these 724 publications were analyzed according to
the following inclusion criteria: contained an AD patient
population according to the National Institute of Neurologi-
cal and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association criteria [26]
and/or the Diagnostic and Statistical Manual for Mental Dis-
orders [27] criteria for AD and mentioned the use of a cogni-
tively intact elderly control group, mean plasma or serum
levels of nutrients, number of AD patients and number of
controls, and mean age or age range of the AD and control
group.For meta-analysis, a minimum of five pAnalysis of the retrieved documents revealed that some of
these publications concerned data that were derived from the
same patient population. In this case, the publication with
the most complete set of data was included. The following
papers were excluded: those concerning other cognitive
disorders (e.g., mild cognitive impairment [MCI], vascular
dementia, frontotemporal dementia, or psychogeriatric
disease), those that included subjects using vitamin supple-
ments, and those not written in English. Botanicals, resver-
atrol, curcumin, b-carotene, and heavy metals (aluminum
and mercury) were also excluded because these are not con-
sidered micronutrients.
This systematic review resulted in the identification of
80 publications that met all inclusion criteria, some of
which described plasma levels of multiple nutrients.ublications was required [28,29].
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All reported comparisons of plasma/serum levels in
AD patients and controls were integrated and summarized
into a final result per nutrient, using meta-analysis (re-
gression) methods [30], according to the PRISMA state-
ment [25]. For each nutrient, we extracted from the
articles the mean and standard deviation of plasma/serum
levels in AD patients and in controls as well as the num-
ber of subjects and the average age per group. To allow
comparison across studies, all plasma/serum levels were
converted to the same unit value. These data were ana-
lyzed using the random-effects meta-analysis model
[30] fitted by restricted maximum likelihood using the
program metareg of Stata (StataCorp. 2001. Statistical
Software: Release 12.1. College Station, TX, USA)
[31]. For this analysis, a minimum of five studies is gen-
erally recognized to be required [28,29].
Because it is known that the plasma levels of several
nutrients can vary with age [32], the meta-analyses were
conducted with and without a correction by meta-
regression for differences in mean age between AD patients
and controls. The final result for a given nutrient was based
on the result of the meta-analysis with age adjustment. Given
the fact that plasma and serum levels were of the same
magnitude, both were used in the same analysis. For clarity,
we use the term plasma in the remainder of this systematic
review.2.3. Analysis of bias
According to the PRISMA statement [25], the quality of
a systematic review depends on the quality of the individual
studies and the absence of bias for their inclusion. To avoid
the risk of bias, general search terms were chosen (such as
nutrition and diet) to guarantee that papers reporting nutrient
levels as a secondary outcome would also be included. The
quality of the studies was assessed by several inclusion
and exclusion criteria (listed in Search strategy and selection
criteria). Furthermore, the results of the meta-analyses were
statistically analyzed for possible bias because of small
studies tending to have larger effects or smaller effects
using a funnel plot accompanied by the Egger’s test [31].
Meta-analyses that are based on small studies reporting
larger (smaller) effects may tend to overestimate (underesti-
mate) the actual outcome. Funnel plots, which plot the stan-
dard error against the reported mean difference for each
publication, can give an indication of the overestimation or
underestimation of the actual difference occurring in the
meta-analysis. We used Egger’s test as implemented in the
Stata program meta-bias [31] to test the association between
standard error and effect size in the funnel plot. For this anal-
ysis, a minimum of eight publications is generally recog-
nized to be required [28,29]. Statistically significant results
of the funnel plot analysis are indicated in the Results
section.2.4. Meta-analysis limited to AD patients and controls
reported not to differ in measures of protein/energy
malnourishment
A secondary objectivewas to explore the presence of differ-
ent plasmanutrient levels betweenADand control subjects that
were reported not to differ in measures of protein/energy mal-
nutrition. Therefore, a meta-analysis was conducted for each
nutrient including only a subset of studies that reported no sig-
nificant differences in bodymass index (BMI), mini nutritional
assessment (MNA) score, or plasma albumin levels between
the AD patients and control subjects [33,34]. Publications
were also included in which the authors explicitly stated that
there were no differences in protein/energy malnourishment
status between AD patients and controls.3. Results
Publications were found concerning the following nutri-
ents: vitamin A (9 studies), vitamin B1 (2 studies), vitamin
B6 (2 studies), folate (31 studies), vitaminB12 (33 studies), vi-
tamin C (8 studies), vitamin D (5 studies), vitamin E (20 stud-
ies), the omega-3 fatty acids DHA and EPA (4 studies), and 7
minerals or trace elements (calcium [4 studies], copper [5 stud-
ies], iron [5 studies], magnesium [3 studies], manganese [2
studies], selenium [4 studies], and zinc [5 studies]). Table 1
provides a summary of this systematic review, listing for
each nutrient the results reported in the retrieved publications.
The primary objectivewas to assess whether differences in
plasma nutrient levels exist between AD patients and cogni-
tively intact elderly controls. Therefore, a meta-analysis was
performed with a correction by meta-regression for differ-
ences in mean age between AD patients and controls. This
meta-analysis was possible for vitamin A, folate, vitamin
B12, vitamin C, vitamin D, vitamin E, copper, iron, and
zinc because our literature search had yielded more than
five publications for each of these nutrients (see Figures 1–9
and Table 2). Significantly lower plasma levels of vitamin
A, vitamin C, vitamin E, folate, and vitamin B12 (P , .001)
and nonsignificantly lower levels of vitamin D (P 5 .075)
and zinc (P 5 .050) were found in AD patients compared
with controls. No significant differences were observed for
plasma levels of copper and iron. These results are based on
a meta-analysis with age adjustment. For completeness, the
results of the meta-analyses without age correction are also
provided in the figures.
Basun and colleagues [35] reported comparisons of plasma
vitamin B12 levels between AD patients and controls for five
different age groups. Because these concerned five indepen-
dent observations, all are shown in Figure 3. Figure 3 further
shows that the results reported by Dominguez and colleagues
[36] and by Postiglione and colleagues [37] deviated from
those reported in the other publications. The reason for this
discrepancymay be attributed to the higher vitaminB12 levels
that were measured in the control group (713 pmol/L in Dom-
inguez et al. [36] and 780 pmol/L in Postiglione et al. [37]) as
Table 1
Results of the systematic review
Nutrient Total number of publications
Total number
of AD patients
Total number of
control subjects
Studies reporting significantly lower
levels in AD patients than in controls
Studies reporting significantly
higher levels in AD patients
than in controls
Studies reporting no significant
differences between AD patients
and controls
Vitamin A 9 studies [44,65,72,74,75,78,100–102] 310 674 4 studies
P , .005 [74]
P , .05 [65,72,78]
5 studies [44,75,100–102]
Folate 31 studies [36,37,46,84,85,103–128] 2108 2447 14 studies
P , .005 [37,46,84,85,104,106,
108,114,123,124,127]
P , .05 [36,109,126]
17 studies [103,105,107,110–113,
115–122,125,128]
Vitamin B12 33 studies [35–37,44,46,49,84,85,103,
105,107–112,114–123,125–131]
2264 2784 9 studies
P , .005 [37,84,114,123,127]
P , .05. [44,46,118,129]
24 studies [35,36,49,85,103,105,
107–112,115–117,119–122,
125,126,128,130,131]
Vitamin C 8 studies [44,74,75,77,79,132–134] 223 211 4 studies
P , .005 [44,74,75,132]
4 studies [77,79,133,134]
Vitamin D 5 studies [47,98,99,135,136] 394 471 2 studies
P , .005 [98,99]
3 studies [47,135,136]
Vitamin E 20 studies [44,65,69,71–78,100,101,
132,133,137–141]
830 1349 9 studies
P , .005 [44,69,72,74,75,78,141]
P , .01 [65]
P , .05 [100]
11 studies [71,73,76,77,101,132,
133,137–140]
Copper 5 studies [39,40,51,53,142] 178 575 1 study
P , .01 [51]
1 study
P 5 .001 [40]
3 studies [39,53,142]
Iron 5 studies [39,51,53,129,142] 153 545 2 studies
P , .05 [39,51]
3 studies [53,129,142]
Zinc 5 studies [39,51,53,142,143] 157 554 2 studies
P , .05 [51,143]
3 studies [39,53,142]
DHA in PL 3 studies [38,41,42] 69 80 2 studies
P , .05 [41]
P , .001 [38]
1 study [42]
EPA in PL 3 studies [38,41,42] 69 80 3 studies
P , .05 [41,42]
P , .001 [38]
DHA in CE 3 studies [38,42,43] 78 106 1 study
P , .001 [43]
1 study
P , .01 [38]
1 study [42]
EPA in CE 3 studies [38,42,43] 78 106 2 studies
P , .05 [42]
P , .001 [43]
1 study [38]
Vitamin B1 2 studies [44,45] 53 50 2 studies
P , .05 [44,45]
Vitamin B6 2 studies [44,46] 48 48 1 study
P , .005 [44]
1 study [46]
Calcium 4 studies [39,47–49] 76 90 1 study
P , .05 [47]
3 studies [39,48,49]
(Continued )
S
.
L
o
p
es
d
a
S
ilva
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
1
0
(2
0
1
4
)
4
8
5
–
5
0
2
4
8
9
T
ab
le
1
R
es
u
lt
s
o
f
th
e
sy
st
em
at
ic
re
v
ie
w
(C
o
n
ti
n
u
ed
)
N
u
tr
ie
n
t
T
o
ta
l
n
u
m
b
er
o
f
p
u
b
li
ca
ti
o
n
s
T
o
ta
l
n
u
m
b
er
o
f
A
D
p
at
ie
n
ts
T
o
ta
l
n
u
m
b
er
o
f
co
n
tr
o
l
su
b
je
ct
s
S
tu
d
ie
s
re
p
o
rt
in
g
si
gn
ifi
ca
n
tl
y
lo
w
er
le
ve
ls
in
A
D
p
at
ie
n
ts
th
an
in
co
n
tr
o
ls
S
tu
d
ie
s
re
po
rt
in
g
si
gn
ifi
ca
n
tl
y
h
ig
h
er
le
ve
ls
in
A
D
p
at
ie
n
ts
th
an
in
co
n
tr
o
ls
S
tu
d
ie
s
re
po
rt
in
g
n
o
si
g
n
ifi
ca
n
t
d
if
fe
re
n
ce
s
b
et
w
ee
n
A
D
p
at
ie
n
ts
an
d
co
n
tr
o
ls
M
ag
ne
si
u
m
3
st
ud
ie
s
[3
9
,5
0,
5
1
]
7
6
8
3
2
st
u
d
ie
s
P
,
.0
0
1
[5
1
]
P
,
.0
1
[5
0
]
1
st
ud
y
[3
9
]
M
an
ga
n
es
e
2
st
ud
ie
s
[5
2
,5
3]
5
4
5
8
2
st
ud
ie
s
[5
2
,5
3]
S
el
en
iu
m
4
st
ud
ie
s
[3
9
,5
1,
5
4
,5
5
]
1
2
9
1
4
1
2
st
u
d
ie
s
P
,
.0
0
1
[5
1
,5
4]
1
st
ud
y
P
,
.0
5
[3
9
]
1
st
ud
y
[5
5
]
A
b
b
re
v
ia
ti
o
n
s:
A
D
,
A
lz
h
ei
m
er
’s
d
is
ea
se
;
D
H
A
,
d
o
co
sa
h
ex
ae
n
o
ic
ac
id
;
P
L
,
p
h
o
sp
h
o
li
pi
d
s;
E
PA
,
ei
co
sa
p
en
ta
en
o
ic
ac
id
;
C
E
,
ch
o
le
st
er
y
l
es
te
r.
N
O
T
E
.
C
ol
u
m
n
s
1
–
4
:
p
u
b
li
ca
ti
on
s
re
tr
ie
ve
d
p
er
n
u
tr
ie
n
t
an
d
n
u
m
b
er
s
o
f
in
cl
u
d
ed
A
D
p
at
ie
n
ts
an
d
co
n
tr
o
ls
.
C
o
lu
m
n
s
5
–
7
:
st
u
d
ie
s
re
p
o
rt
in
g
si
gn
ifi
ca
n
tl
y
lo
w
er
le
ve
ls
(C
o
lu
m
n
5
),
si
g
n
ifi
ca
n
tl
y
h
ig
h
er
le
ve
ls
(C
o
lu
m
n
6
),
an
d
n
o
si
g
n
ifi
ca
n
t
d
if
fe
re
n
ce
s
(C
o
lu
m
n
7
)
in
A
D
p
at
ie
n
ts
v
s
co
n
tr
ol
s.
S. Lopes da Silva et al. / Alzheimer’s & Dementia 10 (2014) 485–502490compared with the values reported for the control subjects in
the other studies.Omissionof these two studies from themeta-
analysis (and from the funnel plot analysis, see next para-
graph) did not change the results.
Subsequent funnel plot analysis was conducted to iden-
tify underestimations or overestimations of the actual differ-
ence [31]. This analysis required a minimum of eight
publications and was possible for vitamin A, folate, vitamin
B12, vitamin C, and vitamin E. All funnel plot analyses were
not significant except for vitamin B12. The funnel plot for
vitamin B12 (P 5 .008) indicated a statistically significant
underestimate of the actual difference. The nonsignificant
results of the funnel plot analyses for vitamin A, folate, vita-
min C, and vitamin E indicated that the results of the meta-
analyses were not biased because of the inclusion of small
studies reporting large effects.
A secondary objectivewas to assess the presence of differ-
ent plasma nutrient levels between AD and control subjects
that were explicitly reported not to differ in measures of pro-
tein and energy nourishment. Therefore, a meta-analysis
with age correction was conducted on a subset of publica-
tions reporting to have included only AD patient and control
populations that did not differ in the status of protein and en-
ergy nourishment (as reflected by BMI, MNA, or albumin).
For vitamin A, folate, vitamin B12, vitamin C, and vitamin
E, sufficient publications were available to allow for the
meta-analysis substudy. The meta-analysis substudies
showed statistically significant lower plasma levels of folate,
vitamin B12, vitamin C, and vitamin E (P .001) in AD pa-
tients compared with controls, whereas a trend toward lower
levels of vitamin A (P 5 .052) were found (see Table 2).
Thus, these findings indicate that even when only AD and
control subjects are taken that are reported not to differ in
signs of protein and energy malnutrition, similar statistically
significant lower micronutrient levels were found in AD pa-
tients compared with cognitively intact elderly controls.
For several nutrients, insufficient publications were re-
trieved to perform the meta-analysis. The results of individ-
ual studies are discussed in the following subsections. None
of these publications reported significantly higher plasma
nutrient levels in AD patients compared with controls, ex-
cept for one study reporting higher levels of DHA in the cho-
lesteryl ester (CE) moiety [38], one study reporting higher
levels of selenium [39], and one study reporting higher levels
of copper [40] (indicated in Column 6 of Table 1).3.1. Fatty acids
The electronic database search with our search string re-
trieved three publications that investigated DHA and EPA
levels in PLs [38,41,42] and three that investigated these
levels in the CE lipid moiety [38,42,43] in the plasma of
AD patients and of cognitively intact elderly controls.
Levels were expressed as weight percentage of total fatty
acids in the particular lipid moiety. The publications by
Corrigan and colleagues [38,42] concerned two different
Unadjusted Overall (REML, I-squared=87%, P < .001)
Glaso '04
Jimenez-Jimenez '97
Baldeiras '08
Polidori '02
Engelhart '05
Polidori '04
Age adjusted Overall (REML meta-regression P < .001)
study
Zaman '92
Connor '97
Bourdel-Marchasson '01
17
37
37
40
437
55
control
20
8
23
n
2.1
1.9
1.8
2.2
1.6
2.7
control
2.1
1.7
2.5
mean
0.4
0.6
0.5
0.5
0.4
0.3
control
0.9
1.1
0.8
sd
20
44
42
35
65
63
AD
10
11
20
n
1.9
1.6
1.8
2.0
1.5
2.0
AD
1.6
1.3
1.9
mean
0.6
0.4
0.5
0.3
0.4
0.4
AD
0.8
0.9
0.7
sd
-0.32 (-0.49, -0.14)
-0.20 (-0.52, 0.12)
-0.31 (-0.53, -0.09)
-0.07 (-0.28, 0.14)
-0.20 (-0.38, -0.02)
-0.11 (-0.22, -0.00)
-0.70 (-0.82, -0.58)
-0.41 (-0.64, -0.17)
difference (95% CI)
-0.57 (-1.18, 0.04)
-0.42 (-1.36, 0.52)
-0.59 (-1.04, -0.14)
mean
10.7
13.5
13.6
14.2
15.9
15.6
(%)
5.5
2.9
8.1
weight
 
AD lower  AD higher 
0-1.5-1.25 -1 -.75 -.5 -.25 .25 .5 .75
vitamin A
Fig. 1. The age-adjusted overall mean difference in plasma vitamin A (retinol) levels (mmol/L) between AD patients and controls was significant (P, .001) and
approximately 20% of the absolute amount in the control subjects. Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; REML, restricted max-
imum likelihood.
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both included in our systematic analysis. The second study
of Corrigan and colleagues [42] only concerned the fatty
acid profiles of the isolated plasma high-density lipoprotein
fraction. With regard to plasma PLs, the individual papers
reported significantly lower levels of DHA (Conquer et al.
[41] P , .05; Corrigan et al. [38] P , .001) and EPA (Con-
quer et al. [41] P, .05; Corrigan et al. [42] P, .05; Corrigan
et al. [38] P, .001) in AD patients compared with their cog-
nitively intact contemporaries (see Table 1). These studies
comprised 80 control subjects and 69 AD patients.
With regard to the CE moiety, one of the three publica-
tions (Corrigan et al. [38] P , .01) reported a significantly
higher weight percentage of DHA in AD patients versus con-
trols. However, Tully et al. [43] reported a significantly
lower weight percentage of DHA in AD patients
(P, .001), whereas in the second study by Corrigan and col-
leagues [42] no significant differences were observed be-
tween AD patients and controls (see Table 1). The weight
percentage of EPA in the CE moiety was found to be signif-
icantly lower in AD patients (vs controls) in the publications
of Corrigan et al. [42] (P , .05) and in the publication of
Tully et al. [43] (P , .001). In the other publication no sta-
tistical difference was reported (see Table 1). These studies
comprised 106 control subjects and 78 AD patients.
Vitamin B1 [44,45] and vitamin B6 [44,46] were each
only mentioned in two publications. The individual papers
reported significantly lower levels of vitamin B1 (Glas€o
et al. [44] P , .05; Molina et al. [45] P , .05) and vitaminB6 (Glas€o et al. [44] P , .005) in AD patients compared
with controls (see Table 1).3.2. Calcium
Four papers were retrieved that measured calcium levels
[39,47–49], including in total 90 control subjects and 76 AD
patients. Of these four studies, one study [47] reported sig-
nificantly (P , .05) lower levels of calcium in AD patients
versus controls (see Table 1). In the other studies, no signif-
icant differences were reported.3.3. Magnesium
Three publications were found to report on plasma mag-
nesium levels in AD and controls [39,50,51], including in
total of 83 control subjects and 76 AD patients. Two
[50,51] of them measured significantly lower plasma levels
of magnesium in AD patients compared with controls
(Vural et al. [51] P , .001; Kurup et al. [50] P , .01) (see
Table 1).3.4. Manganese
Only two publications, including in total 58 controls and
54 AD patients, reported manganese plasma levels [52,53].
In both publications, differences between AD patients and
controls were not significant (see Table 1).
Fig. 2. The age-adjusted overall mean difference in plasma folate levels (nmol/L) between AD patients and controls was significant (P , .001) and
approximately 20% of the absolute amount in the control subjects. Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; REML, restricted max-
imum likelihood.
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Four studies were found that measured plasma selenium
levels in AD patients compared with controls, including in
total 141 control subjects and 129 AD patients
[39,51,54,55]. Two of the studies [51,54] reported
significantly lower levels in AD patients (P , .001),
whereas one study [39] reported significantly higher
(P , .05) levels of selenium in AD patients (see Table 1).4. Discussion
To our knowledge, this is the first systematic comparison
of plasma nutrient levels in AD patients to those in cogni-
tively intact elderly controls. Conclusive evidence that
plasma nutrient levels in AD patients are lower than in
controls had thus far been lacking. The magnitude of the
effect—15–30% lower concentration for several
nutrients—was surprising. Integrating the results of all pub-
lished studies in the current meta-analysis provides an un-
equivocal answer to our research objective for vitamin A,
folate, vitamin B12, vitamin C, and vitamin E (P , .001).
Funnel plotting of these results further showed that the
meta-analyses were not biased because of the inclusion ofsmall studies reporting large effects. In fact, the funnel plot
for vitamin B12 indicated a statistically significant underes-
timate of the actual difference. It is important to note that in
the meta-analysis that included only studies with no differ-
ence inmeasures of protein/energymalnourishment between
AD patients and controls, the same statistically significant
differences were observed, except for vitamin A, for which
a trend was found toward lower levels (P5 .052). This indi-
cates that the lower nutrient levels in AD patients may not be
a mere consequence of protein/energy malnourishment.
Because weight loss and malnutrition are common prob-
lems in AD as well as a predictive factor of mortality, recom-
mendations on the nutritional care in AD have focused on
protein/energy malnutrition, particularly for the end stages
of the disease when this risk increases [56–58]. For
example, in mild-moderate AD (Mini-Mental State Exami-
nation [MMSE] score 5 20), only 3% of the patients were
shown to be malnourished (MNA score , 17.5) [59],
whereas in severe AD (MMSE score , 10), 50% of AD pa-
tients had protein and energy malnutrition [60]. The present
systematic review is the first to focus on the nutritional status
of micronutrients and fatty acids, several of which with sug-
gested potential to modulate pathophysiological processes in
AD but have thus far not been part of recommendations for
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Fig. 3. The age-adjusted overall mean difference in plasma vitamin B12 (cobalamin) levels (pmol/L) between AD patients and controls was significant
(P , .001) and approximately 15% of the absolute amount in the control subjects. Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; REML,
restricted maximum likelihood.
S. Lopes da Silva et al. / Alzheimer’s & Dementia 10 (2014) 485–502 493nutritional and clinical care. The reported MMSE values of
the AD patient populations in the studies that we retrieved
were in the moderate MMSE range of 20 to 10, and the
AD patients were not reported to have protein and energy
malnutrition. This is in agreement with a previous study
that investigated the protein and energy status of a group
of 93 AD patients with an average MMSE of 14.8 6 5.7
[61]. Thus, we believe that the lower levels of plasma nutri-
ents found in the meta-analyses are not due to, and probably
precede, protein and energy malnutrition. The lower plasma
nutrient levels may be caused by altered feeding behavior
[62,63], nutrient absorption, utilization, and metabolism.
In particular, the last two processes have been implicated
in the pathophysiology of AD [64–66].
It is a widely held view that oxidative damage plays an
important role in the neurodegenerative process of AD
[67]. Oxidative stress may lead to an increased use of antiox-
idant molecules and therefore cause a disease-specific
decrease in their circulating levels [65]. Neuronal
membranes are a potential target for the damaging effects
of oxidative stress because of their high content of polyun-
saturated fatty acids, which are vulnerable to oxidation.
Lipid peroxidation can alter membrane composition [68],which is particularly evident in AD. Vitamin A, vitamin C,
vitamin E, and selenium serve as antioxidants to protect
the lipid precursors and the resulting membrane components
from lipid peroxidation. The primary objective of many pub-
lications that reported plasma levels of antioxidants (e.g.,
vitamins A, C, and E) was to investigate whether AD pa-
tients have alterations in their capacity to combat oxidative
stress [65,69–79]. In addition to anthropometric measures
and nutritional examination of vitamin intakes, Bourdel-
Marchasson and colleagues [65] conducted a measurement
of actual levels of lipid peroxidation in AD patients and con-
trols. This study indicated that the lower plasma antioxidant
levels were due to enhanced brain consumption secondary to
an excessive production of free radicals. The lower amounts
of vitamins A, C, and E found in our meta-analysis may be
caused by such increased utilization. This is also expected
for selenium; however, insufficient publications were re-
trieved to assess this hypothesis. Because a proper antioxi-
dant capacity is of pivotal importance to protect neuronal
membranes, a process that is particularly affected in AD,
AD patients may have an increased need for these vitamins
compared with cognitively intact elderly people to compen-
sate for increased utilization.
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S. Lopes da Silva et al. / Alzheimer’s & Dementia 10 (2014) 485–502494In addition to alterations in the utilization of nutrients,
AD pathology has been shown to be accompanied by alter-
ations in the metabolism of nutrients by the liver. One of
the enzymes, peroxisomal D-bifunctional protein, whichUnadjusted Overall (REML, I-squared=95%, P = .031)
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livers of AD patients were shown to contain significantly
lower levels of DHA-containing phosphatidylethanolamineUnadjusted Overall (REML,I-squared=83%, P = .72)
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S. Lopes da Silva et al. / Alzheimer’s & Dementia 10 (2014) 485–502496The publications that were retrieved in our systematic search
also indicated lower levels of DHA in plasma PLs [38,41].
The metabolic change in the de novo DHA synthesis in the
liver may contribute to the lower levels of DHA in plasma
PLs found in AD patients. Circulating DHA can be
obtained from DHA present in some foods and from the
conversion of ALA to DHA in the liver. Hence, because of
the hepatic metabolic alterations, AD patients may need
higher dietary intake of DHA.Unadjusted Overall (REML, I-squared=0, P < .001)
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Fig. 9. A trend (P5 .050) toward lower age-adjusted zinc levels (mg/dL) in AD pat
confidence interval; REML, restricted maximum likelihood.Impaired digestion and absorption of nutrients has also
been reported in AD. For example, absorption of calcium
and zinc depends on active transport by ion channels. Im-
pairments in channel function may lead to impaired dietary
uptake (observed by Ferrier et al. [47]) and lower plasma
levels. Zinc and calcium share many transport and signaling
pathways [80] and have been implicated in the disease pro-
cess [81]. We found a trend toward lower plasma levels of
zinc (P 5 .050) in AD patients. Insufficient publications-6.16 (-9.45, -2.88)
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Table 2
Results of meta-analyses
Nutrient Number of publications
Meta-analysis
In all cases levels
were lower in AD
patients than in
controls
Substudy on AD and control populations reported not to differ in protein
and energy nourishment
Number of publications
Meta-analysis
In all cases levels were
lower in AD vs controls
Vitamin A 9 studies [44,65,72,74,75,78,100–102] P , .001 6 studies [44,65,74,75,78,100] P 5 .052
Folate 31 studies [36,37,46,84,85,103–128] P , .001 14 studies [46,84,105,107,109–112,114,
116,120,122,123,125]
P  .001
Vitamin B12 33 studies [35–37,44,46,49,84,85,103,105,
107–112,114–123,125–131]
P , .001 16 studies [44,46,49,84,105,107,109–112,
114,116,120,122,123,125]
P  .001
Vitamin C 8 studies [44,74,75,77,79,132–134] P , .001 5 studies [44,74,75,79,133] P  .001
Vitamin D 5 studies [47,98,99,135,136] P 5 .075 NA NA
Vitamin E 20 studies [44,65,69,71–78,100,101,132,
133,137–141]
P , .001 11 studies [44,65,69,74,75,78,100,133,137,
139,141]
P  .001
Copper 5 studies [39,40,51,53,142] NS NA NA
Iron 5 studies [39,51,53,129,142] NS NA NA
Zinc 5 studies [39,51,53,142,143] P 5 .05 NA NA
Abbreviations: AD, Alzheimer’s disease; NS, not significant; NA, not applicable.
NOTE. Columns 1–3: meta-analysis per nutrient with included publications. Columns 4–5: meta-analysis substudies using AD and control populations re-
ported not to differ in protein/energy nourishment. In all cases, levels were lower in AD vs controls.
S. Lopes da Silva et al. / Alzheimer’s & Dementia 10 (2014) 485–502 497were retrieved to draw definite conclusions on plasma cal-
cium levels, and more research is warranted.
The reason for the significantly lower B-vitamin levels in
AD patients remains to be elucidated. The meta-analysis
substudies indicate that these lower levels cannot merely
be attributed to differences in nutritional status compared
with controls. The B vitamins vitamin B6, vitamin B12,
and folate are components of the one-carbon metabolism
and are essential to maintain the methylation capacity of
the cell. Folate and vitamin B12 act as cofactors in the reme-
thylation of homocysteine (HCy) to methionine, and vitamin
B6 is the cofactor in the conversion of HCy to cysteine. Hy-
perhomocysteinemia is considered to be a marker for com-
promised B-vitamin status. In AD, increases in plasma
HCy have been observed compared with control subjects
[82–87], and hyperhomocysteinemia can be resolved by
dietary addition of B vitamins [66]. It is currently unclear
whether Hcy is high because of low B-vitamin intake or if
high Hcy and low B-vitamin levels are the result of alter-
ations in liver function and metabolism. Recent research in-
dicates that intake of B vitamins not only decreases plasma
HCy, but it also increases plasma DHA and choline levels in
a dose-dependent manner [88,89]. DHA and choline are
both, as is uridine, rate-limiting precursors in the formation
of synaptic membranes (reviewed by Wurtman et al. [90]).
Low plasma B-vitamin levels in AD may contribute to com-
promised release of DHA and choline into the circulation.
An increase in the intake of B vitamins may not only resolve
effects directly mediated by B vitamins and hyperhomocys-
teinemia, but it may also affect neuronal functioning by cor-
recting the compromised metabolism of other nutritional
substrates.
The lower plasma nutrient levels indicate that patients
with AD have impaired systemic availability of several nutri-ents. Contributing factors might be AD-related alterations in
eating behavior, nutrient absorption, digestion, and metabo-
lism and increased utilization of nutrients due to AD patho-
physiology (e.g., to combat the oxidative stress). At the
same time, the nutrient needs might be increased in AD
(e.g., due to a higher requirement for the formation of neuro-
nal membranes and synapses) [91]. This implies that patients
with AD may benefit from higher nutrient intake to address
the disease-specific requirement and to compensate for their
lower nutrient availability. Thus far, several intervention
studies have investigated the effects of higher intake of vita-
min B, vitamin C, vitamin E, and long-chain omega-3 fatty
acids. Some of these studies that were performed in mild
AD patients or in early-stage AD, such as MCI, have shown
promise [92–95], although others have reported inconclusive
or little improvement in neuropsychological function and
other outcomes [96]. Two multicountry randomized-control
trials investigated the effects of a specific multiple nutrient
enrichment (DHA, EPA, UMP, choline, folate, vitamin B6,
vitamin B12, vitamin C, vitamin E, selenium, and PLs)
through a medical food aiming to provide the nutritional
needs for the formation and functioning of synaptic mem-
branes in AD. These studies showed improved memory
performance of drug-na€ıve patients with mild AD and pre-
served functional connectivity, a derivative of synaptic
function [24,97]. Thus, these studies suggest that
addressing the increased nutritional requirement of the
patient results in improvements in neurophysiological and
neuropsychological alterations that are characteristic of AD.
A systematic review and meta-analysis is limited by the
quality, quantity, and contents of the available publications.
If more studies had been available on omega-3 fatty acids,
vitamin B1, vitamin B6, calcium, magnesium, manganese,
and selenium, we would also have been able to perform
S. Lopes da Silva et al. / Alzheimer’s & Dementia 10 (2014) 485–502498meta-analysis on these nutrients and would have been able to
draw stronger conclusions on differences in their levels be-
tween AD patients and controls. Exploration of the contribu-
tion of differences in dietary intake between AD and control
subjects to plasma nutrient levels was limited by the low
availability of habitual intake data. In all cases, we excluded
the publications that had used subjects on vitamin supple-
ments. With regard to the assessment of the nutritional sta-
tus, we were limited by the various nutritional assessment
procedures that were reported (e.g., plasma albumin levels,
BMI, and MNA). Therefore, it was not possible to use a nu-
merical value for the nutritional status as a confounding vari-
able in the meta-analysis. Hence, we decided to repeat the
meta-analysis as a whole, including only the publications re-
porting that the AD and control populations did not differ in
nutritional status. Because malnutrition appears to be more
prevalent in more advanced stages of AD, it would have
been interesting to investigate whether the differences in
plasma nutrient levels were dependent on the stage in the
AD spectrum. However, only half of the number of publica-
tions reported the mean MMSE score of the included sub-
jects, and those MMSE scores were in the moderate range
of 10 to 20. Therefore, it was not possible to perform the
meta-analysis with disease stage as a confounding variable
or by using only data of mild AD patients.
In conclusion, the current investigation indicates that pa-
tients with AD have impaired systemic availability of several
nutrients, even in the absence of signs of malnutrition. Pro-
vided the postulated role of nutrients in AD, the utility of nu-
trition may currently be underappreciated and offer potential
in AD management. Nutrition-based approaches to reduce
the risk of AD and for the management of diagnosed AD
are potentially attractive because of the relatively low risk
of side effects. The advances in diagnostic methodologies
provide opportunity for earlier intervention in the prodromal
and preclinical stages of AD. Therefore, an interesting future
consideration is to investigate nutrient levels and metabo-
lism in presymptomatic AD, when the damaging subclinical
changes may not have yet accumulated to an irreversible de-
gree, to further explore the potential of nutritional ap-
proaches to reduce the risk of AD.Acknowledgments
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1. Systematic review: To evaluate possible different
systemic availability of micronutrients and fatty
acids between AD patients and cognitively intact el-
derly controls, we searched in literature databases.
We found many publications reporting various re-
sults but no comprehensive review of this area.
Hence, we performed a systematic review and
meta-analysis to generate an overview of this litera-
ture.
2. Interpretation: The highly significant effects across
a range of nutrients provide conclusive evidence
that plasma nutrients levels are lower in AD, and
the lower levels may occur in the absence of, or pre-
cede, signs of protein and energy malnutrition. Pro-
vided the postulated roles for these nutrients in
pathological processes of AD, the current observa-
tions provide a lead for nutritional strategies in AD.
3. Future directions: Additional research is needed to
investigate the changes in AD-specific eating be-
havior, nutrient metabolism, and pathophysiology
causing the lower nutrient levels in AD and to de-
termine when in the disease spectrum the lower
levels start to manifest.References
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